Cyxone AB
Cyxone AB (publ), a clinical stage biotech company, develops disease modifying therapies for autoimmune and autoinflammatory diseases. Its product pipeline comprises Rabeximod, which is in phase II clinical development for the treatment of rheumatoid arthritis; and T20K for the treatment of multiple sclerosis and is in phase I trial. The company was founded in 2015 and is headquartered in Malmö, … Read more
Cyxone AB (CYXO) - Net Assets
Latest net assets as of June 2024: Skr29.55 Million SEK
Based on the latest financial reports, Cyxone AB (CYXO) has net assets worth Skr29.55 Million SEK as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr33.01 Million) and total liabilities (Skr3.46 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr29.55 Million |
| % of Total Assets | 89.51% |
| Annual Growth Rate | 81.01% |
| 5-Year Change | -45.69% |
| 10-Year Change | N/A |
| Growth Volatility | 2196.13 |
Cyxone AB - Net Assets Trend (2015–2023)
This chart illustrates how Cyxone AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Cyxone AB (2015–2023)
The table below shows the annual net assets of Cyxone AB from 2015 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | Skr38.96 Million | -17.01% |
| 2022-12-31 | Skr46.95 Million | +19.66% |
| 2021-12-31 | Skr39.23 Million | -41.54% |
| 2020-12-31 | Skr67.11 Million | -6.46% |
| 2019-12-31 | Skr71.74 Million | +1.68% |
| 2018-12-31 | Skr70.55 Million | +89.99% |
| 2017-12-31 | Skr37.13 Million | +62.63% |
| 2016-12-31 | Skr22.83 Million | +6654.94% |
| 2015-12-31 | Skr338.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cyxone AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 21248200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr8.64 Million | 22.17% |
| Other Comprehensive Income | Skr179.00K | 0.46% |
| Other Components | Skr242.79 Million | 623.16% |
| Total Equity | Skr38.96 Million | 100.00% |
Cyxone AB Competitors by Market Cap
The table below lists competitors of Cyxone AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CENTURY ALUMINUM
BE:EY3
|
$316.31K |
|
NISSAN CHEMICAL IND - Dusseldorf Stock Exchang
DU:NSC
|
$316.32K |
|
China Dongsheng International Inc
PINK:CDSG
|
$316.36K |
|
SULLIDEN MNG CAPITAL
F:14S
|
$316.49K |
|
Morgan Sindall Group PLC
LSE:MGNS
|
$316.21K |
|
Genpact Ltd
STU:35G
|
$315.73K |
|
BABW
BATS:BABW
|
$315.64K |
|
TOKIO MARINE
BE:MH6
|
$315.54K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cyxone AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 46,946,000 to 38,961,000, a change of -7,985,000 (-17.0%).
- Net loss of 22,989,000 reduced equity.
- New share issuances of 1,098,000 increased equity.
- Other comprehensive income increased equity by 46,000.
- Other factors increased equity by 13,860,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-22.99 Million | -59.01% |
| Share Issuances | Skr1.10 Million | +2.82% |
| Other Comprehensive Income | Skr46.00K | +0.12% |
| Other Changes | Skr13.86 Million | +35.57% |
| Total Change | Skr- | -17.01% |
Book Value vs Market Value Analysis
This analysis compares Cyxone AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.05x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.35x to 0.05x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | Skr0.05 | Skr0.02 | x |
| 2016-12-31 | Skr1.77 | Skr0.02 | x |
| 2017-12-31 | Skr1.86 | Skr0.02 | x |
| 2018-12-31 | Skr1.83 | Skr0.02 | x |
| 2019-12-31 | Skr1.54 | Skr0.02 | x |
| 2020-12-31 | Skr1.09 | Skr0.02 | x |
| 2021-12-31 | Skr0.62 | Skr0.02 | x |
| 2022-12-31 | Skr0.48 | Skr0.02 | x |
| 2023-12-31 | Skr0.37 | Skr0.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cyxone AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -59.01%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -446.56%
- • Asset Turnover: 0.12x
- • Equity Multiplier: 1.12x
- Recent ROE (-59.01%) is below the historical average (-55.34%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -47.93% | -771.43% | 0.03x | 1.95x | Skr-195.80K |
| 2016 | -18.23% | -19817.26% | 0.00x | 1.03x | Skr-6.44 Million |
| 2017 | -23.76% | 0.00% | 0.00x | 1.11x | Skr-12.54 Million |
| 2018 | -21.88% | -1543400.00% | 0.00x | 1.07x | Skr-22.49 Million |
| 2019 | -49.02% | -132356.31% | 0.00x | 1.05x | Skr-42.34 Million |
| 2020 | -73.02% | 0.00% | 0.00x | 1.08x | Skr-55.71 Million |
| 2021 | -114.78% | 0.00% | 0.00x | 1.18x | Skr-48.95 Million |
| 2022 | -90.46% | -663.65% | 0.12x | 1.12x | Skr-47.16 Million |
| 2023 | -59.01% | -446.56% | 0.12x | 1.12x | Skr-26.89 Million |
Industry Comparison
This section compares Cyxone AB's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $60,327,288
- Average return on equity (ROE) among peers: -132.31%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cyxone AB (CYXO) | Skr29.55 Million | -47.93% | 0.12x | $316.24K |
| 2cureX AB (2CUREX) | $20.24 Million | -15.50% | 0.13x | $1.38 Million |
| Abliva AB (ABLI) | $63.04 Million | -23.59% | 0.13x | $46.60 Million |
| Ascelia Pharma AB (publ) (ACE) | $180.86 Million | -72.56% | 0.21x | $25.35 Million |
| AcouSort AB (ACOU) | $20.11 Million | -65.68% | 1.12x | $4.82 Million |
| Active Biotech AB (ACTI) | $162.30 Million | -107.35% | 0.93x | $3.55 Million |
| Alzinova AB (ALZ) | $29.39 Million | -8.53% | 0.08x | $4.19 Million |
| AlzeCure Pharma (ALZCUR) | $110.75 Million | -64.44% | 0.06x | $12.56 Million |
| Annexin Pharmaceuticals AB (ANNX) | $20.64 Million | -216.80% | 0.22x | $4.92 Million |
| Alligator Bioscience AB (ATORX) | $6.86 Million | -748.65% | 15.13x | $723.60K |
| Biosergen AS (BIOSGN) | $-10.92 Million | 0.00% | 0.00x | $2.76 Million |